Clinical trial
Safety, Tolerability, and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventative Therapy Among HIV-infected Patients Taking Dolutegravir-based Antiretroviral Treatment
NCT03435146 is registered in ClinicalTrials.gov with The Aurum Institute NPC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Tolerability, and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventative Therapy Among HIV-infected Patients Taking Dolutegravir-based Antiretroviral Treatment
- Lead sponsor
- The Aurum Institute NPC
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 18, 2018
- Completion date
- December 7, 2022
- Enrollment
- 135 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.